Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy.
Androgenic alopecia
Gene editing
Microbubble
Nanoliposome
Protein delivery
Journal
Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
23
08
2019
revised:
27
11
2019
accepted:
25
12
2019
pubmed:
7
1
2020
medline:
15
5
2021
entrez:
6
1
2020
Statut:
ppublish
Résumé
Compared to a plasmid, viral, and other delivery systems, direct Cas9/sgRNA protein delivery has several advantages such as low off-targeting effects and non-integration, but it still has limitations due to low transfer efficiency. As such, the CRISPR/Cas9 system is being developed in combination with nano-carrier technology to enhance delivery efficiency and biocompatibility. We designed a microbubble-nanoliposomal particle as a Cas9/sgRNA riboprotein complex carrier, which effectively facilitates local delivery to a specific site when agitated by ultrasound activation. In practice, we successfully transferred the protein constructs into dermal papilla cells in the hair follicle of androgenic alopecia animals by microbubble cavitation induced sonoporation of our particle. The delivered Cas9/sgRNA recognized and edited specifically the target gene with high efficiency in vitro and in vivo, thus recovering hair growth. We demonstrated the topical application of ultrasound-activated nanoparticles for androgenic alopecia therapy through the suppression of SRD5A2 protein production by CRISPR-based genomic editing.
Identifiants
pubmed: 31901692
pii: S0142-9612(19)30854-3
doi: 10.1016/j.biomaterials.2019.119736
pii:
doi:
Substances chimiques
CRISPR-Associated Protein 9
EC 3.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
119736Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.